At the time of writing, Rigel Pharmaceuticals [RIGL] stock is trading at $1.44, up 1.41%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RIGL shares have gain 7.46% over the last week, with a monthly amount glided 9.09%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 12, March 2024, Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer. In a post published today on Yahoo Finance, Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the appointment of Lisa Rojkjaer, M.D. as Executive Vice President and Chief Medical Officer. Dr. Rojkjaer is an industry veteran with over 20 years of clinical development, regulatory, and medical affairs experience with a focus on hematology and oncology. She is a board-certified hematologist with an international clinical practice background.
From an analyst’s perspective:
Previously, Citigroup downgraded its rating to Neutral on June 09, 2022. On June 08, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $1 on the stock. Cantor Fitzgerald downgraded its rating to a Neutral and decreased its price target to $1 on June 08, 2022. B. Riley Securities initiated its recommendation with a Neutral and recommended $4 as its price target on March 23, 2022. JP Morgan downgraded its rating to Neutral for this stock on November 09, 2020.
For the past year, the stock price of Rigel Pharmaceuticals fluctuated between $0.71 and $1.96. Currently, Wall Street analysts expect the stock to reach $1.5 within the next 12 months. Rigel Pharmaceuticals [NASDAQ: RIGL] shares were valued at $1.44 at the most recent close of the market. An investor can expect a potential return of 4.17% based on the average RIGL price forecast.
Analyzing the RIGL fundamentals
According to Rigel Pharmaceuticals [NASDAQ:RIGL], the company’s sales were 116.88M for trailing twelve months, which represents an -30.20% plunge. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.18%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.22%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is 0.92 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-2.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.4067 points at the first support level, and at 1.3733 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.4667, and for the 2nd resistance point, it is at 1.4933.
Rigel Pharmaceuticals [RIGL] reported earnings per share of $0 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $0.03 and a surprise factor of 100.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.03 per share as compared to estimates of -$0.07 per share, a difference of $0.04 representing a surprise of 57.10%.
Ratios To Look Out For
It is important to note that Rigel Pharmaceuticals [NASDAQ:RIGL] has a current ratio of 1.86. Also, the Quick Ratio is 1.76, while the Cash Ratio stands at 0.62. Considering the valuation of this stock, the price to sales ratio is 2.16.
Transactions by insiders
Recent insider trading involved RODRIGUEZ RAUL R, CEO, President, that happened on Feb 05 ’24 when 30545.0 shares were sold. EVP, Chief Commercial Officer, Santos David A completed a deal on Feb 05 ’24 to sell 8918.0 shares. Meanwhile, EVP & Chief Financial Officer Schorno Dean L sold 7027.0 shares on Feb 05 ’24.
